Galectin: Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024

Galectin Therapeutics Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported net loss was USD 47.05 million compared to USD 41.07 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 0.74 a year ago. Diluted loss per share from continuing operations was USD 0.76 compared to USD 0.74 a year ago. Galectin Therapeutics Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported net loss was USD 47.05 million compared to USD 41.07 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 0.74 a year ago. Diluted loss per share from continuing operations was USD 0.76 compared to USD 0.74 a year ago.